Table 1. Main characteristics of the strains and summary of their translocation, adhesion, invasion and biofilm formation ability.
| Strain | Source | Source | MLST (ST) | Antibiotic resistance | Other features | % TER/ basal TER (min-max) | Translocation | Adhesion | Invasion | Biofilm production | Reference | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coefficient | Classification | Polystyrene | Collagen-I | Collagen-IV | ||||||||||
| Efm106 | OH patient | Faeces | 18 | Amp, HLR-S, Ery | esp, hyl, acm | 90.2–103.6 | 3.70 (2.57–4.82) | High | High | Low | No | Strong | Weak | Sánchez-Díaz et al. 2015 |
| Efm113 | OH patient | Faeces | 117 | Amp, Lvx, HLR-S, HLR-G, Ery | esp, hyl, acm | 95.4–112.2 | 3.17 (2.11–4.24) | High | High | Low | No | No | Weak | Sánchez-Díaz et al. 2015 |
| Efm121 | OH patient | Blood | 117 | Amp, Lvx, HLR-S, Ery | esp, acm | 98–114 | 3.70 (2.65–4.75) | High | Medium | Low | No | No | Weak | Sánchez-Díaz et al. 2015 |
| Efm197 | OH patient | Faeces | 117 | Amp, Lvx, HLR-S, HLR-G, Ery, Lnz | esp, hyl, acm | 96.9–110.8 | 0.87 (-0.19–1.93) | Medium | Medium | Low | No | Weak | Strong | Sánchez-Díaz et al. 2015 |
| Efm217 | Outpatient | Faeces | 25 | Amp, Lvx, HLR-S, Kan, Tet | acm | 97.02–111.9 | 2.16 (1.10–3.21) | High | Low | Low | No | Weak | Weak | Tedim et al. 2015 |
| Efm222 | Outpatient | Faeces | 699 | -- | -- | 101.3–116.3 | -- | Medium | Medium | Low | No | No | Weak | Tedim et al. 2015 |
| Sg1 | Patient | Blood | 34 | Min | pil1 | 105.7–128.9 | NA | Medium | Low | Low | Weak | Strong | Strong | Romero et al. 2015 |
| Sg6 | Patient | Blood | 35 | Clin, Fos | pil1 | 103.1–125.2 | NA | Medium | Low | Low | No | Strong | Strong | Romero et al. 2015 |
| Sg74 | Cow | Faeces | 24 | Hlr-S, Ery, Min, Clin, Sxt | pil1 | 106.4–127.2 | NA | Low | Low | Low | Weak | Strong | Strong | Romero et al. 2015 |
| Sg78 | Calf | Faeces | 28 | Clin, Sxt, Van, Q/D | -- | 113.2–128.3 | NA | Medium | Low | Medium | Weak | Weak | Strong | Romero et al. 2015 |
| Efc29212 | ATCC | Control | 30 | -- | -- | -- | -- | -- | -- | -- | Weak | Weak | Strong | www.atcc.org |
| Lr925 | CECT 925T | Control | -- | -- | -- | -- | -- | No | -- | -- | -- | -- | -- | www.cect.org |
Abbreviations: MLST, multilocus sequence typing; ST, sequence type; TER, transepithelial electrical resistance; OH, oncohaematological; Amp, ampicillin; HLR-S, high level resistance to streptomycin, Ery, erythromycin; Lvx, levofloxacin; HLR-G high level resistance to gentamicin; Lnz, linezolid; Min, minocycline, Clin, clindamycin; Fos, fosfomycin; Stx, sulfamethoxazole; Van, vancomycin; Q/D, quinupristin/dalfopristin; esp, enterococcal surface protein; hyl, glycosyl hydrolase; acm, adhesin of collagen of E. faecium; pil1, Pil1 pilus.